SCHEMBL4584826

SCHEMBL4584826

O=C1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(O)n3)[nH]2)CC1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.50
CSNK1A1 P48729 1/20 0.50
RPS6KA3 P51812 1/20 0.50
MAPK14 Q16539 9/20 0.49
MAPK13 O15264 7/20 0.49
MAPK12 P53778 7/20 0.49
MAPK11 Q15759 7/20 0.49
MAPK9 P45984 4/20 0.49
RAF1 P04049 3/20 0.49
JAK3 P52333 1/20 0.42
BRAF P15056 2/20 0.41
TGFBR1 P36897 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4585063 0.89 MAPK14 (0.58) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL4583940 0.87 MAPK14 (0.65) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL8099899 0.87 CSNK1D (0.55) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL4585062 0.85 MAPK14 (0.50) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL4583956 0.85 MAPK14 (0.57) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL4585004 0.84 MAPK14 (0.44) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL4583203 0.82 MAPK14 (0.52) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL4585719 0.78 MAPK14 (0.43) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL4585531 0.77 MAPK14 (0.57) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13
SCHEMBL8304260 0.76 CSNK1D (0.47) CSNK1DCSNK1A1RPS6KA3MAPK14MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0889726-A4 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORP (US) 1999-07-21 EP claimed
EP-0889726-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1999-01-13 EP claimed
WO-1997025048-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 WO claimed
EP-1539121-A4 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2008-08-13 EP disclosed
EP-1545535-A4 TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE SCIOS INC (US) 2008-06-04 EP disclosed
EP-1583535-A4 METHODS FOR TREATING DIABETES SCIOS INC (US) 2008-03-19 EP disclosed
EP-1583535-A2 METHODS FOR TREATING DIABETES SCIOS INC. (US) 2005-10-12 EP disclosed
EP-1545535-A2 TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE SCIOS INC. (US) 2005-06-29 EP disclosed
EP-1539121-A2 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC. (US) 2005-06-15 EP disclosed
WO-2005032551-A1 TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE SCIOS INC. (US) 2005-04-14 WO disclosed
WO-2005030091-A2 STENTS AND INTRA-LUMINAL PROSTHESES CONTAINING MAP KINASE INHIBITORS SCIOS INC. (US) 2005-04-07 WO disclosed
EP-1021173-A1 USE OF CSAID?TM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2000-07-26 EP disclosed
EP-1019396-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SmithKline Beecham Corporation (US) 2000-07-19 EP disclosed
EP-0889726-A4 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORP (US) 1999-07-21 EP disclosed
WO-1999018942-A1 USE OF CSAIDTM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS IMPERIAL COLLEGE INNOVATIONS LTD. (GB) 1999-04-22 WO disclosed
WO-1999001452-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 WO disclosed
EP-0889726-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1999-01-13 EP disclosed
EP-0889888-A1 NOVEL TREATMENT FOR CNS INJURIES SMITHKLINE BEECHAM CORPORATION (US) 1999-01-13 EP disclosed
WO-1997035856-A1 NOVEL TREATMENT FOR CNS INJURIES SMITHKLINE BEECHAM CORPORATION (US) 1997-10-02 WO disclosed
WO-1997025048-A1 NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 WO disclosed